In her latest ESMO perspectives On target column: Multidisciplinary Tumor Boards in harmony: mission impossible?, VHIO’s Elena Garralda, Principal Investigator of our Early Clinical Drug Development Group, and Director of VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, contemplates the concordance rates of treatment recommendations between central consensus and multidisciplinary tumor boards (MTBs).
Drawing on the results of a prospective study (Kage H et al.) (1) that were presented during last month’s virtual 2021 ESMO Congress, 18-21 September, Elena illuminates the potential impact of MTBs on multidisciplinary care, but also cautions that better strategies, support systems and open access tools, such as Cancer Core Europe’s Molecular Tumor Board Portal (2), will be required in order to achieve higher concordance, particularly for those tumor types with less defined treatment options.
To read Elena’s latest On Target column and access this month’s ESMO perspectives, please visit: https://perspectives.esmo.org/latest-edition/slider-content/multidisciplinary-tumour-boards-in-harmony-mission-possible.
###
- 519MO – Concordance analysis of treatment recommendations between central consensus and multidisciplinary tumor boards. Kage, K. Sunami, Y. Naito, T. Amano, D. Ennishi, M. Imai, M. Kanai, H. Kenmotsu, K. Komine, T. Koyama, T. Maeda, S. Morita, Y. Saigusa, D. Sakai, T. Yamanaka, S. Kohsaka, K. Tsuchihara, T. Yoshino. Ann Oncol (2021) 32 (suppl_5): S583-S620. 10.1016/annonc/annonc699.
- Cancer Core Europe’s Molecular Tumor Board Portal: https://www.mtbp.org/.
